📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-17 17:45
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
27 announcements match the current filters (relevance ≥ 5).
CRISIL Reaffirms GMM Pfaudler's Ratings at 'AA-/Stable' and 'A1+' for Rs 600 Cr Facilities
CRISIL Ratings has reaffirmed GMM Pfaudler Limited's credit ratings for its bank loan facilities totaling INR 600 crore. The long-term bank facilities have been reaffirmed at 'CRISIL AA-/Stable', while the short-term facilities are reaffirmed at 'CRISIL A1+'. The rated total of INR 600 crore represents approximately 16.4% of the company's TTM revenue of Rs 3,655 crore and 72.1% of its net worth of Rs 832 crore. This reaffirmation highlights continued credit stability and financial profile backing its existing debt operations.
Confidence: HIGH
What changedCRISIL Ratings reaffirmed existing ratings of AA-/Stable (long-term) and A1+ (short-term) on Rs 600 crore of bank loan facilities.
Why it mattersA reaffirmation confirms steady lender confidence and ongoing access to funding at competitive interest rates without rating downgrades.
Total facilities rated: INR 600 croreLong-term rating: Crisil AA-/StableShort-term rating: Crisil A1+Rated facilities vs TTM revenue: ~16.4%Rated facilities vs Net worth: ~72.1%
📅 Short termNeutral impact on stock price as ratings are unchanged and represent a standard periodic reaffirmation.
📈 Long termLimited; reflects continuity in balance sheet health and borrowing cost profile.
⚠ Risk flags
- Cyclical end-user exposure (chemical and pharma capex slowdowns)
Key Highlights
CRISIL reaffirmed ratings on total bank loan facilities of INR 600 crore
Long-term bank loan facilities reaffirmed at 'Crisil AA-/Stable'
Short-term bank loan facilities reaffirmed at 'Crisil A1+'
Rating action executed on September 17, 2026
👀 What to Watch
Monitor upcoming quarterly earnings and working capital management to see if operational cash flows support maintaining this stable credit profile.
GMM Pfaudler: Group CFO Alexander Poempner Resigns; Ankit Nayyar Appointed Effective Nov 4, 2026
GMM Pfaudler's Board has approved the resignation of Group CFO and KMP Alexander Poempner, effective post Q2 FY27 results on November 4, 2026, after a 5-year tenure. He will be succeeded by Ankit Nayyar, who joined as Deputy CFO in May 2026 and previously served as CFO of PI Health Sciences. To ensure a smooth transition, Mr. Poempner will continue with the company until December 31, 2026. GMM Pfaudler operates at an annualized TTM revenue run-rate of ₹3,655 Cr with a market cap of ₹5,495 Cr.
Confidence: HIGH
What changedAlexander Poempner is stepping down as Group CFO and KMP, replaced internally by Deputy CFO Ankit Nayyar effective November 4, 2026.
Why it mattersA planned leadership succession with an existing Deputy CFO minimizes disruption across the company's global finance operations, which support ₹3,655 Cr in TTM revenue.
Effective date of CFO handover: November 4, 2026Outgoing CFO transition end date: December 31, 2026Outgoing CFO tenure: 5 yearsTTM Revenue context: ₹3655 Cr
📅 Short termNeutral market impact expected since the planned transition until December 31, 2026, and internal promotion mitigates typical CFO departure risks.
📈 Long termLimited operational disruption; the incoming CFO brings deep specialty chemical and pharma domain expertise relevant to GMM Pfaudler's primary client industries.
Key Highlights
Group CFO Alexander Poempner resigns effective November 4, 2026, after a 5-year tenure
Current Deputy CFO Ankit Nayyar appointed as incoming Group CFO and KMP on November 4, 2026
Outgoing CFO will support the organization through December 31, 2026, for an orderly handover
Incoming CFO brings nearly 20 years of experience across pharma, specialty chemicals, and manufacturing
👀 What to Watch
Track the upcoming Q2 FY27 results scheduled for November 4, 2026, and monitor financial commentary and capital allocation strategy under the new CFO leadership.
GMM Pfaudler: Group CFO Alexander Poempner Resigns; Deputy CFO Ankit Nayyar Appointed Successor
GMM Pfaudler has announced the resignation of its Group CFO Alexander Poempner, who is stepping down to pursue outside opportunities after a 5-year tenure. The resignation takes effect on November 4, 2026, coinciding with the Q2 FY27 board meeting, though Poempner will remain until December 31, 2026, to assist in the transition. The Board has appointed current Deputy CFO Ankit Nayyar as the new Group CFO effective November 4, 2026. Nayyar brings roughly two decades of experience, having previously served as CFO of PI Health Sciences.
Confidence: HIGH
What changedGroup CFO Alexander Poempner resigned, and Deputy CFO Ankit Nayyar was appointed to take over the role on November 4, 2026.
Why it mattersA planned leadership succession from Deputy CFO to CFO minimizes disruption to financial strategy, global M&A integrations, and cost management across GMM Pfaudler's ₹3,655 Cr revenue base.
Effective date of CFO change: November 4, 2026Outgoing CFO transition period ends: December 31, 2026Outgoing CFO tenure: 5 yearsIncoming CFO experience: nearly two decades
📅 Short termNeutral market impact expected as the succession was internally planned, with the outgoing CFO providing a multi-month handover.
📈 Long termLimited operational disruption; the incoming CFO has domain experience across pharmaceuticals and chemicals, aligning with GMM Pfaudler's core markets.
⚠ Risk flags
- Key personnel transition risks in global financial consolidation and M&A execution
Key Highlights
Alexander Poempner resigns as Group CFO and KMP after a 5-year tenure
Cessation takes effect on November 4, 2026, following the Q2 FY27 board meeting
Transition support extended with Poempner continuing until December 31, 2026
Ankit Nayyar appointed Group CFO effective November 4, 2026, bringing nearly 20 years of experience
👀 What to Watch
Track the upcoming Q2 FY27 financial results on November 4, 2026, and monitor financial disclosures during the leadership transition through December 31, 2026.
GMM Pfaudler Appoints Ankit Nayyar as Group CFO Effective November 4, 2026
GMM Pfaudler has announced the resignation of Group CFO Alexander Poempner, who is stepping down to pursue new opportunities after a 5-year tenure. The Board has appointed Ankit Nayyar, the current Deputy CFO who joined the company in May 2026, as the new Group CFO effective November 4, 2026, coinciding with the Q2 FY27 results. To ensure an orderly transition, Mr. Poempner will continue with the company through December 31, 2026. Nayyar brings nearly two decades of experience, including previous CFO leadership at PI Health Sciences and finance roles at Bayer and Monsanto.
Confidence: HIGH
What changedAlexander Poempner is stepping down as Group CFO, and internal successor Ankit Nayyar (Deputy CFO) is promoted to Group CFO effective November 4, 2026.
Why it mattersA planned leadership transition with an internal successor and a two-month handover window minimizes disruption across the company's global finance and M&A operations.
Effective Date of Appointment: November 4, 2026Handover Period End Date: December 31, 2026Outgoing CFO Tenure: 5 yearsIncoming CFO Experience: nearly two decades
📅 Short termNeutral market impact expected as the succession was pre-planned with Deputy CFO elevation and an overlap period through December 31, 2026.
📈 Long termLimited operational disruption; the incoming CFO's background in specialty chemicals, pharma, and M&A aligns closely with GMM Pfaudler's end-market focus.
⚠ Risk flags
- Key management transition risk, though mitigated by an internal promotion and transition period
Key Highlights
Alexander Poempner resigns as Group CFO effective November 4, 2026, after a 5-year tenure
Outgoing CFO will support the transition until December 31, 2026
Ankit Nayyar appointed Group CFO effective November 4, 2026; previously joined as Deputy CFO in May 2026
Incoming CFO has nearly 20 years of experience across pharmaceuticals, specialty chemicals, and manufacturing
👀 What to Watch
Track the upcoming Q2 FY27 financial results on November 4, 2026, and monitor communication around capital allocation and global integration under the incoming CFO.
GMM Pfaudler Appoints Ankit Nayyar as Group CFO Succeeding Alexander Poempner Effective Nov 4, 2026
GMM Pfaudler announced that Group CFO Alexander Poempner has resigned to pursue outside opportunities after a 5-year tenure. He will step down following the Q2 FY27 board meeting scheduled for November 4, 2026, and remain through December 31, 2026, to assist the transition. The board has appointed Deputy CFO Ankit Nayyar as the new Group CFO effective November 4, 2026. Nayyar joined the company in May 2026 and brings nearly two decades of finance experience, previously serving as CFO of PI Health Sciences.
Confidence: HIGH
What changedAlexander Poempner has resigned as Group CFO and will be succeeded by current Deputy CFO Ankit Nayyar effective November 4, 2026.
Why it mattersA planned leadership succession from within (Deputy CFO) minimizes execution disruptions across GMM Pfaudler's global finance and M&A operations.
Effective handover date: November 4, 2026Outgoing CFO final exit date: December 31, 2026Outgoing CFO tenure: 5 yearsIncoming CFO sector experience: nearly two decades
📅 Short termNeutral reaction expected given the pre-planned internal succession and overlap period lasting through December 31, 2026.
📈 Long termLimited operational disruption expected; incoming CFO Ankit Nayyar brings relevant domain expertise in specialty chemicals, pharma, and M&A integration.
⚠ Risk flags
- Key managerial transition during ongoing global operational integration
Key Highlights
Alexander Poempner steps down as Group CFO and KMP effective November 4, 2026
Transition support extended with outgoing CFO remaining until December 31, 2026
Ankit Nayyar appointed as incoming Group CFO effective November 4, 2026
Nayyar joined as Deputy CFO in May 2026 with nearly 20 years of sector experience
Poempner completes a 5-year tenure with the GMM Pfaudler Group
👀 What to Watch
Track the upcoming Q2 FY27 earnings release planned for November 4, 2026, and watch for commentary on financial strategy continuity and capital allocation under the incoming CFO.
GMM Pfaudler Appoints Ankit Nayyar as Group CFO Effective Nov 4, 2026; Alexander Poempner Resigns
GMM Pfaudler has announced the resignation of Alexander Poempner as Group CFO & KMP, effective post the Q2 FY27 board meeting scheduled for November 4, 2026, after a 5-year tenure. He will be succeeded by Ankit Nayyar, who joined the company as Deputy CFO in May 2026. Nayyar brings nearly 20 years of experience, including previous CFO leadership at PI Health Sciences and senior finance roles at Bayer-Monsanto. To facilitate a smooth handover, Poempner will remain with the organization through December 31, 2026.
Confidence: HIGH
What changedAlexander Poempner is stepping down as Group CFO, and internal recruit Ankit Nayyar (Deputy CFO) is being elevated to Group CFO effective November 4, 2026.
Why it mattersA planned transition with overlap minimizes disruption to ongoing operations, global integrations, and financial controls for a global business generating ₹3,655 Cr in TTM revenue.
Effective date of CFO change: November 4, 2026Outgoing CFO transition end date: December 31, 2026Incoming CFO experience: nearly two decadesTTM Revenue scale managed: Rs 3655 Cr
📅 Short termNeutral market impact expected as the succession involves an internal candidate and an orderly two-month handover period through year-end.
📈 Long termLimited operational disruption; the incoming CFO's background in pharmaceuticals, specialty chemicals, and M&A aligns directly with GMM Pfaudler's core markets and bolt-on strategy.
⚠ Risk flags
- Executive turnover at the Group CFO level
- None material
Key Highlights
Alexander Poempner resigns as Group CFO after a 5-year tenure to pursue external opportunities
Appointment of Ankit Nayyar as Group CFO & KMP effective from November 4, 2026
Outgoing CFO Alexander Poempner will remain with the group until December 31, 2026, ensuring transition support
Ankit Nayyar joined the company in May 2026 as Deputy CFO and holds nearly 20 years of finance experience
👀 What to Watch
Track the seamless operational transition during the upcoming Q2 FY27 earnings release scheduled for November 4, 2026, and watch for any commentary on long-term capital allocation strategies.
GMM Pfaudler CEO - International Business Thomas Kehl Retires Effective Aug 31, 2026
GMM Pfaudler Limited has informed the exchanges that Mr. Thomas Kehl, Chief Executive Officer - International Business, has retired from the services of the company effective from the close of business hours on August 31, 2026. Consequently, Mr. Kehl ceases to be a Senior Management Personnel. With GMM Pfaudler generating TTM revenue of ₹3,655 Cr and operating ~20 manufacturing facilities globally, international operations remain a core driver of performance. The company has not yet named an immediate successor in this filing.
Confidence: HIGH
What changedMr. Thomas Kehl stepped down from his role as CEO - International Business due to retirement on August 31, 2026.
Why it mattersInternational business forms the backbone of GMM Pfaudler's global presence (~40% global GLE market share); smooth executive transition is key to ongoing integration and operational execution.
Effective Date of Cessation: August 31, 2026TTM Revenue (Context): ₹3655 CrMarket Cap (Context): ₹4342 Cr
📅 Short termLimited immediate operational impact expected as day-to-day international facility management remains operational under respective regional heads.
📈 Long termEnsuring stable leadership in the overseas business is critical for maintaining cross-border operational efficiencies and pursuing non-GLE diversification targets.
⚠ Risk flags
- Transition risk in international business leadership
- Successor details not yet disclosed in this filing
Key Highlights
Mr. Thomas Kehl retired as Chief Executive Officer - International Business effective close of business hours on August 31, 2026.
Ceases to be a Senior Management Personnel pursuant to SEBI LODR Regulation 30 disclosures.
Company oversees ~20 global manufacturing facilities with TTM revenue standing at ₹3,655 Cr.
👀 What to Watch
Track upcoming management commentary and subsequent exchange filings for details on the successor or leadership restructuring for the international business division.
GMM Pfaudler Repays EUR 7 Million Debt via Subsidiary GMM International
GMM Pfaudler's wholly owned subsidiary, GMM International S.a.r.l., has repaid EUR 7 million of outstanding debt to its lenders. The repayment was funded entirely through internal accruals, fulfilling the timeline guidance provided in its Q1 FY27 earnings release. This deleveraging step strengthens the balance sheet relative to its reported total debt of Rs 250 crore.
Confidence: HIGH
What changedGMM International S.a.r.l. has cleared EUR 7 million of lender debt using internal cash generation.
Why it mattersDemonstrates healthy cash flow generation capable of self-funded deleveraging, lowering interest burden on consolidated earnings.
Debt repaid: EUR 7 millionFunding source: Internal accrualsTotal debt (Context): Rs 250 CrDebt-to-Equity (Context): 0.30
📅 Short termPositive sentiment from meeting guidance on debt reduction ahead of schedule.
📈 Long termContinued deleveraging enhances return ratios (ROCE at 11.0%) and expands room for disciplined bolt-on M&A and organic growth.
Key Highlights
Repaid EUR 7 million of debt facility availed by subsidiary GMM International S.a.r.l.
Debt repayment funded entirely through internal accruals
Completed ahead of/by the guided timeline of end of Q2 FY27 indicated on August 5, 2026
Supports deleveraging against total reported debt of Rs 250 crore (D/E of 0.30)
👀 What to Watch
Track the upcoming Q2 FY27 balance sheet updates to assess the overall reduction in consolidated finance costs and net debt levels.
Rs 2,289 Cr Order Backlog: GMM Pfaudler Reports 20% YoY Growth and Global Reorganization
GMM Pfaudler reported a record order backlog of Rs 2,289 crore, marking a 20% increase year-on-year. The company is undergoing a major structural transformation, moving from geographic silos to four global technology-led divisions (CRT, PPT, HET, PST) to improve operational efficiency and cross-selling. Management noted that the Q1 order intake of Rs 1,007 crore consists primarily of shorter-cycle projects (10-12 months) compared to last year's multi-year contracts, providing higher revenue visibility for FY27. Cost optimization efforts are underway, including shifting engineering functions to lower-cost centers in India and Poland.
Confidence: HIGH
What changedThe company transitioned from a geographic operating model to four global technology divisions and reported a 20% increase in its order backlog.
Why it mattersThe reorganization aims to unify global operations and improve capital allocation, while the shorter-cycle backlog suggests faster revenue realization compared to previous years.
Order Backlog: Rs 2,289 crQ1 Order Intake: Rs 1,007 crBacklog vs TTM Revenue: 64.9%Q1 Order Intake vs TTM Revenue: 28.5%Interest Cost Range: 6% to 7%CRT Division Revenue (Q1): Rs 466 cr
📅 Short termThe record backlog and shift toward shorter execution cycles provide a positive outlook for revenue growth in the coming quarters.
📈 Long termThe structural shift to a global integrated model could lead to better margins and market share if execution is successful across the four new divisions.
⚠ Risk flags
- Execution risks during major organizational restructuring
- High concentration in pharma and chemical sectors (75-80% of GLE revenue)
- Geopolitical risks affecting international shipments
Key Highlights
Order backlog reached a record Rs 2,289 crore, a ~20% increase compared to the previous year.
Q1 FY27 order intake stood at Rs 1,007 crore, with a focus on projects executable within 10-12 months.
CRT (Corrosion Resistance Technologies) division reported Q1 revenues of Rs 466 crore.
Management expects average interest costs to remain between 6% and 7% for FY27.
The company is consolidating non-critical activities into a Global Engineering Center (GEC) to optimize costs.
👀 What to Watch
Monitor the conversion of the shorter-cycle order book into revenue over the next 2-3 quarters to verify management's execution outlook. Watch for margin expansion as the new global divisional structure aims to reduce redundant costs and improve factory utilization.
GMM Pfaudler Q1 FY27: PAT Surges 118% YoY to ₹22.1 Cr; Order Backlog Reaches ₹2,289 Cr
GMM Pfaudler reported a 16% YoY revenue growth to ₹925 Cr for Q1 FY27, though EBITDA margins compressed to 10.1% from 12.7% in the year-ago period. Net profit surged 118% YoY to ₹22.1 Cr, primarily due to a lower base and reduced exceptional items. Order intake remained robust at ₹1,007 Cr (up 16% QoQ), with non-traditional sectors like mining and petrochemicals now contributing 45% of new orders. The company is reorganizing into four global divisions and plans to repay approximately EUR 7 million in debt by the end of Q2 FY27.
Confidence: HIGH
What changedThe company is transitioning from a complex post-acquisition structure to a simplified four-division global model and has shifted its dividend frequency from semi-annual to annual.
Why it mattersThe shift toward non-traditional industries (45% of orders) reduces the company's historical over-reliance on the cyclical pharma and chemical sectors, potentially stabilizing long-term order inflows.
Q1 Revenue: ₹925 CrOrder Intake vs TTM Revenue: 28.5%Order Backlog: ₹2,289 CrEBITDA Margin: 10.1%Debt Repayment Target: EUR 7 million
📅 Short termThe strong order intake and high YoY PAT growth are likely to be viewed positively by the market, though margin pressure remains a concern.
📈 Long termThe structural reorganization and diversification into mining and oil & gas are significant for long-term stability, but the company needs to demonstrate margin recovery to justify its high P/E multiple.
⚠ Risk flags
- EBITDA margin compression from 12.7% to 10.1% YoY
- High sector concentration in pharma/chemicals (55% of orders)
- Geopolitical risks affecting global manufacturing sites
Key Highlights
Revenue grew 16% YoY to ₹925 Cr, representing approximately 26% of TTM revenue.
Order backlog stands at ₹2,289 Cr, providing revenue visibility for roughly 7-8 months.
PAT increased 118% YoY to ₹22.1 Cr, although PAT margins remain low at 2.4%.
Non-traditional industry order intake share rose to 45% in Q1 FY27, up from 33% in FY24.
Planned debt repayment of ~EUR 7 million (approx. ₹65 Cr) scheduled for completion by Q2 FY27.
👀 What to Watch
Monitor the execution of the ₹2,289 Cr backlog and the impact of the global restructuring on operating margins, which have compressed YoY. Watch for the successful repayment of EUR 7 million debt as a sign of improving cash flow management.
Q1 FY27 PAT up 118% YoY to ₹22 Cr; Order Intake crosses ₹1,000 Cr
GMM Pfaudler reported a strong Q1 FY27 with revenue growing 16% YoY to ₹925 Cr. While EBITDA margins contracted to 10.1% (down from the previous year), Profit After Tax (PAT) surged 118% YoY to ₹22 Cr, driven by improved earnings flow-through. The company achieved a robust quarterly order intake of ₹1,007 Cr, representing approximately 28.6% of TTM revenue, which pushed the total backlog to ₹2,289 Cr. Management also announced a corporate reorganization into four global divisions and a planned debt repayment of ~EUR 7 million by Q2 FY27.
Confidence: HIGH
What changedGMM Pfaudler reported a sharp recovery in PAT and strong order momentum; it also reorganized into four global divisions and shifted dividend frequency to annual.
Why it mattersThe record order intake (₹1,007 Cr) indicates a recovery in demand from core pharma and chemical sectors, while the debt repayment plan strengthens the balance sheet.
Q1 FY27 Revenue: ₹925 CrQ1 FY27 PAT: ₹22 CrOrder Intake vs TTM Revenue: ~28.6%Total Backlog vs TTM Revenue: ~64.9%EBITDA Margin: 10.1%Debt Repayment Target: EUR 7 million
📅 Short termThe triple-digit PAT growth and strong order intake are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe reorganization into four global divisions and focus on debt reduction suggest a structural shift toward higher efficiency and better cash generation over the next few years.
⚠ Risk flags
- EBITDA margins remain under pressure (10.1% vs 11.4% TTM average)
- High P/E ratio of 62.4 requires sustained high growth
- Concentration in pharma and chemical sectors (75-80% of GLE revenue)
Key Highlights
Revenue increased 16% YoY to ₹925 Cr, though it saw a marginal 2% decline QoQ.
PAT grew significantly by 118% YoY to ₹22 Cr, reflecting better operational flow-through.
Quarterly order intake reached ₹1,007 Cr, a 16% increase on a sequential (QoQ) basis.
Order backlog stands at ₹2,289 Cr, up 20% compared to the same period last year.
Planned repayment of approximately EUR 7 million debt by the end of Q2 FY27 using internal accruals.
👀 What to Watch
Investors should monitor the execution of the ₹2,289 Cr backlog and observe if the new four-division organizational structure successfully restores EBITDA margins toward the TTM average of 11.4%.
GMM Pfaudler Q1 FY27: Consolidated Revenue Grows 16% YoY to ₹924.76 Cr
GMM Pfaudler reported a consolidated revenue of ₹924.76 Cr for Q1 FY27, marking a 16.4% growth over ₹794.55 Cr in Q1 FY26. However, standalone performance showed signs of pressure, with standalone net profit declining 33% YoY to ₹11.16 Cr from ₹16.70 Cr. The international business remains the dominant contributor, with overseas subsidiaries accounting for ₹706.11 Cr (approx. 76%) of consolidated revenue. While top-line growth is healthy, standalone margin compression due to higher employee costs and lower other income warrants attention.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results, showing a shift where international operations are sustaining growth while the standalone Indian business faces profitability headwinds.
Why it mattersAs a global leader in glass-lined equipment with 40% market share, GMM Pfaudler's results are a proxy for global chemical and pharmaceutical capital expenditure cycles.
Consolidated Revenue (Q1): ₹924.76 CrYoY Revenue Growth: 16.4%International Revenue Contribution: ₹706.11 CrStandalone Net Profit: ₹11.16 CrStandalone EPS (Basic): ₹2.48
📅 Short termThe stock may see neutral to slightly cautious movement as the market weighs healthy consolidated revenue growth against declining standalone profitability.
📈 Long termLong-term value depends on the successful integration of international acquisitions and diversification into high-growth areas like bioplastics and nuclear components.
⚠ Risk flags
- Standalone margin compression
- High concentration in the chemical sector (55-60% of GLE revenue)
- Rising employee benefit costs
Key Highlights
Consolidated revenue from operations increased 16.4% YoY to ₹924.76 Cr.
International subsidiaries contributed ₹706.11 Cr to revenue with a net profit of ₹11.28 Cr.
Standalone net profit fell to ₹11.16 Cr, down from ₹16.70 Cr in the same quarter last year.
Standalone employee benefit expenses increased significantly to ₹38.18 Cr from ₹26.69 Cr YoY.
Standalone Profit Before Tax (PBT) stood at ₹14.64 Cr compared to ₹22.36 Cr in Q1 FY26.
👀 What to Watch
Investors should monitor the recovery in the chemical and pharma sectors, which account for 75-80% of GLE revenue, and track the management's progress in non-GLE segments like lithium purification and nuclear power.
₹2 Final Dividend: GMM Pfaudler Sets July 28, 2026, as Record Date
GMM Pfaudler has fixed July 28, 2026, as the record date for a final dividend of ₹2 per share for FY26, subject to shareholder approval at the AGM on August 4, 2026. The company reported FY26 consolidated revenue of ₹3,524 crore, up 10% YoY, while the order backlog grew significantly by 34% to ₹2,194 crore. A key agenda for the upcoming AGM includes the appointment of Gregory Gelhaus as the new Group CEO. Despite steady revenue growth, consolidated PAT for FY26 was ₹51.82 crore, impacted by exceptional items related to site closures and transformation programs.
Confidence: HIGH
What changedThe company has finalized the timeline for its FY26 final dividend payout and scheduled its 63rd Annual General Meeting to vote on leadership changes and financial adoptions.
Why it mattersWhile the dividend yield is modest (~0.26%), the substantial 34% growth in order backlog provides critical revenue visibility for FY27 amidst a challenging environment for the chemical and pharma sectors.
Final Dividend: ₹2 per shareRecord Date: 28-Jul-2026FY26 Consolidated Revenue: ₹3,524 crOrder Backlog: ₹2,194 crDividend vs CMP: ~0.26%
📅 Short termThe stock is likely to remain neutral with minor adjustments around the ex-dividend date; investor focus will be on the management's commentary during the AGM.
📈 Long termThe company's diversification strategy into non-glass-lined equipment (now ~45% of orders) and the integration of global acquisitions like SEMCO are structural positives for long-term resilience.
⚠ Risk flags
- High concentration in chemical and pharma sectors (75-80% of GLE revenue)
- Geopolitical and trade barrier risks affecting global manufacturing facilities
- Relatively high P/E of 55.6 despite flat PAT growth
Key Highlights
Final dividend of ₹2 per equity share proposed for the financial year 2025-26
Record date for dividend eligibility and AGM participation set for July 28, 2026
Order backlog increased by 34% YoY to reach ₹2,194 crore as of March 2026
Order intake for FY26 stood at ₹3,714 crore, representing a 20% YoY growth
Consolidated EBITDA for FY26 reported at ₹403 crore with an 11% YoY increase
👀 What to Watch
Investors should track the AGM on August 4, 2026, for the formal approval of the dividend and the confirmation of the new Group CEO, which marks a significant leadership transition.
GMM Pfaudler Q4 FY26: Order Intake Surges 20% to INR 3,714 Cr; Backlog Up 34%
GMM Pfaudler reported a steady FY26 with a 10% revenue increase and an 11% rise in EBITDA to INR 403 crores. The company's order intake grew significantly by 20% to INR 3,714 crores, with the opening backlog for FY27 up by 34%, providing strong revenue visibility. Diversification efforts are yielding results, as 50% of new orders now come from non-traditional sectors like semiconductors and defense. Financial health remains robust with a net debt to EBITDA ratio of 0.4x and free cash flow generation of INR 367 crores.
Key Highlights
Order intake for FY26 reached INR 3,714 crores, a 20% year-on-year increase
Opening backlog as of April 1st is up 34%, ensuring high revenue visibility for the coming year
India business outperformed with a 40% growth in PAT and 24% growth in EBITDA
Diversification strategy successful with 50% of orders from non-chemical and non-pharma sectors
Net debt to adjusted EBITDA improved to 0.4x from 0.5x, supported by INR 367 crores in free cash flow
👀 What to Watch
Investors should focus on the strong order backlog and the company's successful pivot to non-traditional industries which mitigates the slowdown in the chemical sector. Monitor the realization of cost-saving benefits from European restructuring in upcoming quarters.
GMM Pfaudler Appoints Gregory Gelhaus as Group CEO; Strengthens Senior Management Team
GMM Pfaudler has announced the appointment of Mr. Gregory Gelhaus as Group CEO and Key Managerial Personnel effective May 21, 2026. Mr. Gelhaus, a member of the promoter family, previously served as the Group's Chief Transformation Officer and has extensive experience at Global Blue and PwC. The company also strengthened its leadership by appointing Mr. Ankit Nayyar (former PI Health Sciences CFO) as Deputy CFO and Mr. Massimo Serapioni as CEO of the Corrosion-Resistant Technologies division. Concurrently, two executives, Mr. Manish Shah and Mr. Ulf Wittmann, have stepped down from Senior Management roles due to organizational restructuring.
Key Highlights
Appointment of Mr. Gregory Gelhaus as Group CEO and KMP effective May 21, 2026, subject to shareholder ratification.
Mr. Ankit Nayyar, former CFO of PI Health Sciences and veteran of Pfizer and Bayer, joins as Deputy CFO.
Mr. Massimo Serapioni appointed as Senior Management Personnel for the Corrosion-Resistant Technologies division.
Mr. Manish Shah and Mr. Ulf Wittmann cease to be SMPs due to organizational restructuring but remain employees.
The new Group CEO is the son-in-law of Mr. Ashok Patel and brother-in-law of Mr. Tarak Patel, indicating a promoter-led leadership transition.
👀 What to Watch
Investors should monitor the impact of this leadership transition and organizational restructuring on the company's execution and growth strategy. The professional credentials of the new Deputy CFO are a positive sign for financial governance.
GMM Pfaudler FY26 Standalone Net Profit Rises 40% to ₹59.3 Cr; Declares ₹1 Final Dividend
GMM Pfaudler reported a strong standalone performance for the financial year ended March 31, 2026, with revenue from operations growing 12% YoY to ₹1,034.21 crore. Standalone net profit for FY26 increased significantly to ₹59.32 crore from ₹42.25 crore in the previous year. The company recommended a final dividend of ₹1 per share, bringing the total dividend for FY26 to ₹2 per share. Furthermore, the board approved the appointment of Gregory Gelhaus as the new Group CEO, marking a key leadership transition.
Key Highlights
Standalone Revenue from operations increased 12.3% YoY to ₹1,034.21 crore in FY26.
Standalone Net Profit for FY26 rose 40.4% to ₹59.32 crore compared to ₹42.25 crore in FY25.
Recommended a final dividend of ₹1 per equity share (Face Value ₹2); total FY26 dividend stands at ₹2 per share.
Appointed Gregory Gelhaus as Group Chief Executive Officer effective May 21, 2026.
Q4 FY26 standalone revenue grew to ₹288.87 crore from ₹252.22 crore in the corresponding quarter last year.
👀 What to Watch
Investors should take note of the robust bottom-line growth and the leadership transition at the CEO level. The steady dividend payout and revenue growth suggest a stable outlook, making it a positive hold for long-term investors.
GMM Pfaudler FY26 Revenue Up 10% to ₹3,524 Cr; Order Backlog Surges 34% to ₹2,194 Cr
GMM Pfaudler reported a steady 10% YoY revenue growth to ₹3,524 Cr for FY26, supported by a strong 20% increase in annual order intake. While reported PAT grew 5% to ₹52 Cr, adjusted PAT excluding exceptional items like severance costs stood significantly higher at ₹99 Cr. The company's order backlog reached a record ₹2,194 Cr, providing high revenue visibility for the coming year. Additionally, the balance sheet strengthened with Net Debt/Equity improving to 0.1x and a final dividend of ₹1 per share was recommended.
Key Highlights
Consolidated Revenue grew 10% YoY to ₹3,524 Cr, with Q4 FY26 revenue rising 17% YoY to ₹944 Cr.
Order intake for FY26 increased by 20% to ₹3,714 Cr, leading to a record backlog of ₹2,194 Cr, up 34% YoY.
EBITDA margin remained stable at 11.4% for the full year, with absolute EBITDA rising 11% to ₹403 Cr.
Net Debt/Equity ratio improved from 0.2x to 0.1x, supported by free cash flow generation of ₹367 Cr.
Diversification strategy is gaining momentum, with non-traditional sectors (Oil & Gas, Defense, Nuclear) now contributing 33% of total order intake.
👀 What to Watch
Investors should take confidence in the record order backlog and the company's successful diversification away from pure pharmaceuticals. The improving debt profile and appointment of a new Group CEO suggest a focus on operational efficiency and global scaling.
GMM Pfaudler FY26 Revenue up 10% to ₹3,524 Cr; Order Backlog Surges 34% to ₹2,194 Cr
GMM Pfaudler reported a steady FY26 with consolidated revenue growing 10% to ₹3,524 crore and EBITDA rising 11% to ₹403 crore. While the India business showed robust growth with PAT up 40% YTD, the international business faced headwinds in Europe, leading to facility closures and restructuring. A significant highlight is the 34% growth in order backlog to ₹2,194 crore, providing strong revenue visibility for the next year. The company also announced a total dividend of ₹2 per share for the fiscal year and appointed a new Group CEO to lead its global transformation.
Key Highlights
Consolidated FY26 revenue grew 10% YoY to ₹3,524 crore, while Q4 revenue rose 17% to ₹944 crore.
Order intake increased by 20% YTD to ₹3,714 crore, resulting in a record closing backlog of ₹2,194 crore.
India operations outperformed with YTD PAT growth of 40% on a revenue of ₹1,034 crore.
Q4 EBITDA margins compressed to 8.0% compared to the full-year average of 11.4% due to geopolitical pressures and European headwinds.
Board recommended a final dividend of ₹1 per share, bringing the total FY26 dividend to ₹2 per share.
👀 What to Watch
Investors should monitor the execution of the European restructuring and the transition under the new Group CEO, Gregory Gelhaus. While the strong order backlog provides revenue visibility, margin recovery in international markets is the critical factor for future stock performance.
GMM Pfaudler Appoints Gregory Gelhaus as Group CEO; Restructures Senior Management
GMM Pfaudler has appointed Mr. Gregory Gelhaus as Group CEO and Key Managerial Personnel effective May 21, 2026. Mr. Gelhaus, previously the Chief Transformation Officer and a Wharton MBA, is a member of the promoter family. The company also elevated Deputy CFO Ankit Nayyar and Division CEO Massimo Serapioni to Senior Management roles. Concurrently, two other executives, Manish Shah and Ulf Wittman, have ceased to be Senior Management Personnel following an organizational restructuring.
Key Highlights
Mr. Gregory Gelhaus appointed as Group CEO and KMP effective May 21, 2026.
Mr. Ankit Nayyar (Deputy CFO) and Mr. Massimo Serapioni (CEO-CRT) elevated to Senior Management Personnel.
Mr. Manish Shah and Mr. Ulf Wittman cease to be SMP due to organizational restructuring but remain employees.
New CEO Gregory Gelhaus is the son-in-law of Mr. Ashok Patel and brother-in-law of Mr. Tarak Patel.
👀 What to Watch
Investors should monitor the transition in leadership and how the organizational restructuring impacts the company's operational efficiency and global strategy. Watch for any shifts in corporate governance given the CEO's relationship with the promoter family.
GMM Pfaudler FY26 Net Profit Rises 40% to ₹59.3 Cr; Recommends ₹1 Dividend & Appoints New Group CEO
GMM Pfaudler reported a strong financial performance for FY26, with standalone revenue growing 12% to ₹1,034 crore and net profit increasing 40% to ₹59.3 crore. The board recommended a final dividend of ₹1 per share, bringing the total dividend for the year to ₹2. A significant leadership transition was announced with Gregory Gelhaus taking over as Group CEO. Despite an exceptional item of ₹12.69 crore during the year, the company maintained healthy margins and improved its earnings per share from ₹9.40 to ₹13.20.
Key Highlights
Standalone Revenue from operations grew 12.3% YoY to ₹1,034.21 crore in FY26.
Net Profit for the full year increased significantly by 40.4% to ₹59.32 crore compared to ₹42.25 crore in FY25.
Recommended a final dividend of ₹1 per share (50% of face value), totaling ₹2 for the full financial year.
Appointment of Mr. Gregory Gelhaus as the new Group CEO to lead the next phase of growth.
Earnings Per Share (EPS) improved to ₹13.20 from ₹9.40 in the previous fiscal year.
👀 What to Watch
Investors should view the strong bottom-line growth and leadership transition positively. Monitor the new CEO's strategy for global operations and the integration of recent acquisitions.
